The chromatin landscape of high-grade serous ovarian cancer metastasis identifies regulatory drivers in post-chemotherapy residual tumour cells
Authors:
Open Access
- 28 September 2024
- journal article
- research article
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-12
Abstract
Disease recurrence following chemotherapy is a major clinical challenge in ovarian cancer (OC), but little is known regarding how the tumour epigenome regulates transcriptional programs underpinning chemoresistance. We determine the single cell chromatin accessibility landscape of omental OC metastasis from treatment-naïve and neoadjuvant chemotherapy-treated patients and define the chromatin accessibility profiles of epithelial, fibroblast, myeloid and lymphoid cells. Epithelial tumour cells display open chromatin regions enriched with motifs for the oncogenic transcription factors MEIS and PBX. Post chemotherapy microenvironments show profound tumour heterogeneity and selection for cells with accessible chromatin enriched for TP53, TP63, TWIST1 and resistance-pathway-activating transcription factor binding motifs. An OC chemoresistant tumour subpopulation known to be present prior to treatment, and characterised by stress-associated gene expression, is enriched post chemotherapy. Nuclear receptors RORa, NR2F6 and HNF4G are uncovered as candidate transcriptional drivers of these cells whilst closure of binding sites for E2F2 and E2F4 indicate post-treated tumour having low proliferative capacity. Delineation of the gene regulatory landscape of ovarian cancer cells surviving chemotherapy treatment therefore reveals potential core transcriptional regulators of chemoresistance, suggesting novel therapeutic targets for improving clinical outcome.Keywords
Funding Information
- RCUK | Medical Research Council (MR/S02235X/1)
- Wellbeing of Women (ELS810)
- DH | National Institute for Health Research (NIHR 203326, NIHR 205029)
This publication has 58 references indexed in Scilit:
- RORα Binds to E2F1 To Inhibit Cell Proliferation and Regulate Mammary Gland Branching MorphogenesisMolecular and Cellular Biology, 2014
- Wnt some lose some: transcriptional governance of stem cells by Wnt/β-catenin signalingGenes & Development, 2014
- Slow-Cycling Therapy-Resistant Cancer CellsStem Cells and Development, 2011
- Molecular mechanisms of cisplatin resistanceOncogene, 2011
- p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53Cell Death & Differentiation, 2011
- Ovarian Cancer Development and MetastasisThe American Journal of Pathology, 2010
- Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovaryThe Journal of Pathology, 2010
- ZNF423 Is Critically Required for Retinoic Acid-Induced Differentiation and Is a Marker of Neuroblastoma OutcomeCancer Cell, 2009
- MEIS and PBX homeobox proteins in ovarian cancerEuropean Journal of Cancer, 2007
- p63 expression in epithelial ovarian tumorsInternational Journal of Gynecological Cancer, 2006